Skip to main content
Clinical Trials/NCT05165862
NCT05165862
Completed
Not Applicable

Evaluation and Monitoring of the Protocol for the Management of Post Operative Atrial Fibrillation Based on Intravenous Beta-blockers in Cardiac Surgery

University Hospital, Brest1 site in 1 country54 target enrollmentFebruary 1, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Post Operative Atrial Fibrillation
Sponsor
University Hospital, Brest
Enrollment
54
Locations
1
Primary Endpoint
Heart Rate
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

Objectives The aims of this study is to evaluate the efficacy and tolerance of our post-operative AF management protocol after cardiac surgery, including beta-blockers, digoxin, amiodarone.

Methods This study concerns patients From brest university Hospital who underwent cardiac surgery between November 2019 and November 2021. Patients with a previous history of atrial arrhythmias were excluded. The primary endpoint is assess effectiveness of service protocol to maintain cardiac frequency below. 110 bpm. The secondary endpoints included hemodynamic tolerance and outcomes.

Detailed Description

Background Atrial fibrillation (AF) is the most common complication after open heart surgery. Its reported incidence is about 30%, and it is associated with a significant increase rate of thromboembolic events, respiratory failure, a longer lenght of stay in hospital and mortality. (1 ;2) Gillinov's study has shown equivalent effectiveness of a rhythm control and rate control strategy, in AF patients after cardiac surgery, with increased side effects in patients treated with rhythm control agents. (3) The introduction of beta-blockers can be poorly tolerated hemodynamically in patients hospitalized in intensive care unit, unless untroducing a cardio-selective beta-blocker.. Methods Patients who underwent a cardiac surgery from Novembre 2019 to Novembre 2021 were included. Patients with a previous history of atrial arrhythmias were excluded. The primary endpoint is assess effectiveness of service protocol to maintain cardiac frequency below. 110 bpm. The secondary endpoints included hemodynamic tolerance and outcomes.

Registry
clinicaltrials.gov
Start Date
February 1, 2020
End Date
October 16, 2021
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • POAF after cardiac surgery non-opposition formulated

Exclusion Criteria

  • pregnant woman opposition hemodynamic unstability with inotropic drugs or CI\<2 L/min/m2

Outcomes

Primary Outcomes

Heart Rate

Time Frame: 72 hours (3 days)

HR \< 110 BPM

Secondary Outcomes

  • sinusal Rythm(72hours ( 3 days))

Study Sites (1)

Loading locations...

Similar Trials